The purpose of this study is to test the effectiveness, safety and side effects of the ibrutinib for patients with marginal zone lymphoma. The study drug is believed to block a special protein that helps blood cancer cells live and grow. The study drug, Ibrutinib, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia or mantle cell lymphoma in patients who have received at least one prior treatment. It has not been approved for the type of cancer being being studied in this trial.

This study is being done to see if giving RAD001 can reduce the chance of relapse when it is given to patients with diffuse large B-cell lymphoma that is in complete remission. Rad001 is currently not approved by the FDA for use in this situation therefore, this treatment is considered experimental.